大部分患者将不会死于滤泡性淋巴瘤，这是非常肯定的。
Most patients will not die from follicular lymphoma, and that's very reassuring.
目的讨论淋巴滤泡瘤样增生与滤泡性淋巴瘤的鉴别诊断。
Objective To discuss the differential diagnosis between tumor-like follicular hyperplasia and follicular lymphoma.
作者描述88例CD5+的滤泡性淋巴瘤临床病理学特征（男性53例，女性35例；
We describe the clinicopathologic features of 88 cases of CD5+ follicular lymphoma (53 men, 35 women;
目的系统评价大剂量化疗后自体干细胞移植一线治疗滤泡性淋巴瘤的临床疗效与安全性。
ObjectiveTo assess the effectiveness and safety of high-dose chemotherapy following autologous stem cell transplantation in first-line treatment of follicular lymphoma.
除了代表潜在的生物标记物外，伴有缺陷BCR信号的细胞存在可提供滤泡性淋巴瘤新的靶点。
In addition to representing a potential biomarker, the existence of cells with defective BCR signaling may provide new targets against follicular lymphoma. -jcl.
此外，一项二期研究将利妥昔单抗和pembrolizumab联合来治疗复发的滤泡性淋巴瘤。
Additionally, a phase II study is looking at the combination of rituximab and pembrolizumab (Keytruda) for patients with relapsed follicular lymphoma (NCT02446457).
自体干细胞移植在滤泡性淋巴瘤的一线治疗中除临床试验之外不宜采用。(证据等级：强，中等)。
Autologous stem cell transplantation has no role in first line therapy for FL outside a clinical trial (Strong, Moderate).
观察等待是无症状的晚期滤泡性淋巴瘤常用的策略，但是对于这些患者来说美罗华单药治疗也是一个选项。
Watch and wait (WAW) is a common approach for asymptomatic, advanced stage follicular lymphoma (FL), but single-agent rituximab is an alternative for these patients.
我们的研究旨在评价利妥昔单抗加化疗一线治疗的滤泡性淋巴瘤患者使用利妥昔单抗维持治疗2年的疗效。
We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen.
PI3K抑制剂idelalisib和BTK抑制剂ibrutinib对复发的滤泡性淋巴瘤显示出很好的潜力。
The PI3K deltainhibitor idelalisib (Zydelig) and the BTK inhibitor ibrutinib (Imbruvica) have shown promise for patients with relapsed follicular lymphoma.
阐释：滤泡性淋巴瘤患者在免疫化疗作为一线治疗后使用利妥昔单抗维持治疗2年，能显著改善无进展生存（PFS）。
INTERPRETATION: 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS.
二期的CheckMate- 140试验正在探索用nivolumab治疗经cd 20抗体和烷化剂治疗后进展的滤泡性淋巴瘤。
The phase II CheckMate-140 trial is exploring nivolumab (Opdivo) for patients with follicular lymphoma following progression on a CD20 antibody and an alkylating agent (NCT02038946).
“这种应答率是有意义的，尽管不像霍奇金病那么高，但是依然很不错，”莱昂纳德说，“问题是，你是否专门针对滤泡性淋巴瘤来开发这种药？”
"These responses are meaningful, not as dramatic as we have seen in Hodgkin's, but it is meaningful," said Leonard. "The question is, 'can you develop this drug in follicular lymphoma?"
在一个30例患者的小规模研究中，pidilizumab加利妥昔单抗在复发的滤泡性淋巴瘤中取得了66%的总有效率，其中大部分是完全缓解。
In a small 30-patient study, pidilizumabplus rituximab demonstrated an ORR of 66% in relapsed follicular lymphoma, which primarily consisted of complete responses.
2016年2月底，FDA批准了对接受过利妥昔单抗治疗的滤泡性淋巴瘤患者使用抗CD20单抗obinutuzumab和苯达莫司汀联合的方案。
In late February 2016, the FDA approved the anti-CD20 agent obinutuzumab(Gazyva) in combination with bendamustine for patients with follicular lymphoma following rituximab-based therapy.
滤泡性B细胞淋巴瘤是一种非霍奇金淋巴瘤，肿瘤疫苗是治疗是根据肿瘤细胞的生物学特殊性。
The cancer vaccines rely on a biological quirk of follicular B-cell lymphoma, which is a type of non-Hodgkin's lymphoma.
如果你的肿瘤对初始治疗无效，你的治疗选择详见复发或难治性滤泡淋巴瘤的治疗部分。
If your disease does not respond to initial treatment, your treatment options are detailed below under Treatment of Recurrent or Refractory Follicular Lymphoma.
如果你的肿瘤对初始治疗无效，你的治疗选择详见复发或难治性滤泡淋巴瘤的治疗部分。
If your disease does not respond to initial treatment, your treatment options are detailed below under Treatment of Recurrent or Refractory Follicular Lymphoma.
应用推荐